September 10, 2020

ProSciento Closes Growth Financing from 1315 Capital Read More »

September 1, 2020

ProSciento Appoints Stephen Mullennix as Chief Financial Officer Read More »


View Recent Webinar


January 8, 2021

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials. Read More »

December 1, 2020

ProSciento’s State-of-the-Art Clinical Research Center for Metabolic Studies Read More »

December 14, 2019

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption Read More »

Stay Connected

Would you like to receive updates from ProSciento?

I'm interested in receiving: